Chinese startup with Merck vet at the helm acquires rights to Oyster Point's eye disease nasal spray
With the Chinese drug market starting to bear fruit, Western drugmakers have looked to wiggle their way in, often leaning on local partners to do …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
